profit from every $100 of sales.
$0$100
Insight Molecular Diagnostics
$2.39-3.24% today
-68.3% in 1 year
1-year low $2.391-year high $8.48
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Insight Molecular Diagnostics sold, what it kept, and what it did with the cash.
Sales went from $958,000 in 2022 to $4.06 million in 2025, with -$50.2 million of profit last year.
SalesProfit
Insight Molecular Diagnostics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Insight Molecular Diagnostics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Insight Molecular Diagnostics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 2 | 2 | 4 | |
| -0 | 0 | 1 | 2 | |
| -29 | -22 | -23 | -31 | |
| -13 | -23 | -59 | -48 | |
| -73 | -28 | -61 | -50 | |
| -20.00 | -3.75 | -4.66 | -1.65 | |
| -1.9% | 27.5% | 39.3% | 56.7% | |
| -3,011.7% | -1,491.5% | -1,235.9% | -754.1% | |
| -7,609.8% | -1,848.4% | -3,225.0% | -1,238.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 100 | 75 | 35 | 26 |
| Cash | 20 | 9 | 9 | 12 |
| Total debt | 4 | 3 | 4 | 3 |
| Total liabilities | 66 | 54 | 47 | 57 |
| 34 | 20 | -12 | -31 | |
| 6 | 8 | 13 | 30 | |
| -38.7% | -84.0% | – | – | |
| -212.6% | -135.7% | 494.2% | 159.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -46 | -23 | -21 | -22 | |
| 4 | 0 | 1 | 3 | |
| -50 | -24 | -21 | -25 | |
| Dividends paid | – | – | – | – |
| 0 | 1 | 5 | 0 | |
| 10 | 3 | 2 | 2 |
Valuation
- –
- –
- –
- -4.9×
- 19.3×
- –
- –
- -32.4%
- -64.2%
- 0.0%
Profitability
- 56.7%
- -754.1%
- -1,238.5%
- -699.9%
- -197.4%
- 101.1%
- 684.6%
- -195.0%
- -223.5%
- 392.1%
Growth
- +61.8%
- –
- −19.5%
- –
- +61.8%
Financial health
- -0.2×
- -0.11
- 13.6%
- -280.5×
- 1.27
- 1.23
- 0.16
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 9%of 889
Bottom 2%of 987
What analysts expect
- Average price target
- $10.50
- Range
- $9.00 – $12.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.28 | -0.26 | −7.1% |
| Mar 26, 2026 | -0.27 | -0.24 | −13.7% |
| Nov 10, 2025 | -0.34 | -0.24 | −41.7% |
| Aug 11, 2025 | -0.30 | -0.23 | −30.4% |
| May 12, 2025 | -0.26 | -0.24 | −8.3% |
| Mar 24, 2025 | 0.48 | -0.43 | +211.6% |
| Nov 12, 2024 | -0.98 | -0.44 | −122.7% |
| Aug 8, 2024 | -0.36 | -0.56 | +35.7% |
News
NetApp introduces new architecture for AI factories at Insight; analysts react positivelySeeking Alpha · Sep 30, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/6Passes 1 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
48No pass
Benjamin Graham
15No pass
Philip Fisher
67Pass
Peter Lynch
–Not enough data
Joel Greenblatt
2No pass
Charlie Munger
59No pass
Terry Smith
55No pass
Questions about Insight Molecular Diagnostics
Is Insight Molecular Diagnostics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Insight Molecular Diagnostics AI analysis
What does Insight Molecular Diagnostics do?
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. It is in Biotechnology.
Does Insight Molecular Diagnostics pay a dividend?
No. Insight Molecular Diagnostics does not pay a dividend at the moment.
Is Insight Molecular Diagnostics stock halal?
Yes. Insight Molecular Diagnostics passes our halal screen: its business is permitted and its debt is 4% of its market value, under the 30% limit. How we check
How has Insight Molecular Diagnostics stock done over the past year?
Down 68.3% over the past twelve months, to $2.39. It traded between $2.39 and $8.48 and is 71.8% below its high.
Who are Insight Molecular Diagnostics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Insight Molecular Diagnostics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.